Most Read Articles
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course
Christina Lau, 22 Oct 2015
A 21-gene expression assay can identify patients with early-stage breast cancer who can skip adjuvant chemotherapy without facing an increased risk of recurrence at 5 years.
Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.

Multidisciplinary management of HCC improves therapy access, patient survival

22 Sep 2017
Constant changes in the healthcare system have warranted the need for continuous updates and improvements in the structure of the orientation programme.

Management of patients with hepatocellular carcinoma (HCC) through a multidisciplinary tumour board (MDTB) results in significantly higher rates of receipt of therapy and improved survival, according to a recent study.

Researchers conducted a database analysis of all patients with HCC managed through MDTB from 2007 until 2011 to determine and compare utilization of therapies and outcomes for HCC patients managed through MDTB with those who were not. They also created a database of all HCC patients from 2002 to 2011, not managed through MDTB.

There were 306 patients with HCC managed through MDTB from 2007 to 2011 compared with 349 from 2002 to 2011 who were not.

No significant differences were recorded in baseline demographic or model for end-stage liver disease at presentation. Patients managed through MDTB were associated with presentation at an earlier tumour stage and with lower serum alpha fetoprotein (AFP; p=0.007).

Patients managed through MDTB were more likely to receive any treatment for HCC (odds ratio, 2.80; 95 percent CI, 1.71 to 4.59; p<0.0001), independent of model for end-stage liver disease score, serum AFP and tumour stage. Also, patients managed through MDTB had significantly greater survival compared to those who were not (19.1±2.5 vs 7.6±0.9 months; p<0.0001).

Management through MDTB, receipt of any HCC treatment, lower serum AFP, receipt of liver transplant and T2 tumour stage were the independent predictors for improved survival.

“Given the complexity of managing [HCC], it is widely accepted that a multidisciplinary team approach (tumour boards) offers the best approach to individualize therapy,” according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course
Christina Lau, 22 Oct 2015
A 21-gene expression assay can identify patients with early-stage breast cancer who can skip adjuvant chemotherapy without facing an increased risk of recurrence at 5 years.
Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.